Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's EV-to-FCF or its related term are showing as below:
HKSE:06922'
s EV-to-FCF Range Over the Past 10 Years
Min: -221.46 Med: -21.32 Max: -10.79
Current: -93.18
During the past 6 years, the highest EV-to-FCF of Cryofocus Medtech (Shanghai) Co was -10.79. The lowest was -221.46. And the median was -21.32.
HKSE:06922's EV-to-FCF is ranked worse than 100% of 410
companies
in the Medical Devices & Instruments industry
Industry Median: 23.64
vs HKSE:06922: -93.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryofocus Medtech (Shanghai) Co's PE Ratio (TTM) for today is calculated as:
Cryofocus Medtech (Shanghai) Co's share price for today is HK$2.79.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryofocus Medtech (Shanghai) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.135.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cryofocus Medtech (Shanghai) Co EV-to-FCF Related Terms
Cryofocus Medtech (Shanghai) Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryofocus Medtech (Shanghai) Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's EV-to-FCF falls into.
Cryofocus Medtech (Shanghai) Co's current Enterprise Value is HK$670.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryofocus Medtech (Shanghai) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-7.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) has a EV-to-FCF of -93.18 as of Sep. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. According to the industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #999999 out of 410 companies in the Medical Devices & Instruments industry.
Is Cryofocus Medtech (Shanghai) Co's EV-to-FCF too high?
Cryofocus Medtech (Shanghai) Co's current EV-to-FCF is -93.18. Based on the distribution chart, Cryofocus Medtech (Shanghai) Co ranks #999999 out of 410 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cryofocus Medtech (Shanghai) Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryofocus Medtech (Shanghai) Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cryofocus Medtech (Shanghai) Co ranks #999999 out of 410 companies for EV-to-FCF. This places Cryofocus Medtech (Shanghai) Co in the lower half of its industry. The industry median EV-to-FCF is 23.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cryofocus Medtech (Shanghai) Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryofocus Medtech (Shanghai) Co's current EV-to-FCF is -93.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryofocus Medtech (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co (HKSE:06922) is currently considered Possible Value Trap. The stock's GF Value™ is HK$21.01, compared to a current price of HK$2.79 — trading 86.7% below its estimated fair value. The current EV-to-FCF is -93.18. Cryofocus Medtech (Shanghai) Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cryofocus Medtech (Shanghai) Co (HKSE:06922), the current EV-to-FCF is -93.18 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryofocus Medtech (Shanghai) Co (HKSE:06922) Overvalued in 2026?
Based on GuruFocus' analysis, Cryofocus Medtech (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$2.79 is trading 86.7% below its estimated GF Value™ of HK$21.01.
GuruFocus considers Cryofocus Medtech (Shanghai) Co to be Possible Value Trap.
Key valuation signals for HKSE:06922:
EV-to-FCF: -93.18
GF Value™: HK$21.01 vs. price of HK$2.79 (86.7% below fair value)
No single metric tells the full story. See the HKSE:06922 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products. The company uses liquid nitrogen as the main cryogenic source for cryotherapy systems by leveraging liquid nitrogen cryoablation technology and flexible catheter technology. The products offered by the company include: Bladder Cryoablation System, Pulmonary Nodule Localization Needle, and Endoscopic Clip for Anastomosis, among others. Geographically, the company's revenue is generated from the sale of medical consumables and devices in the Chinese Mainland.
61GF Score
Get the complete analysis for HKSE:06922
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06922 has been successfully added to your 
